Kyowa Hakko Kirin California, Inc. (KKC) is a wholly-owned US subsidiary of Kyowa Hakko Kirin Co., Ltd. KKC serves as one of Kyowa Hakko Kirin's R&D centers in the United States, and facilitates the company's business and product development efforts in North America. We are focused on developing antibody based therapeutics in four major disease areas: oncology, renal diseases, immune disorders and allergy, by using proprietary technology such as the KM Mouse™, Potelligent® and Complegent®.
Since 1988, KKC has been a major corporate sponsor of the La Jolla Institute for Allergy and Immunology (LIAI), a not-for-profit research institute. In July 2006, together with LIAI, we moved to our new three-story state-of-the-art facility to further expand our research efforts on infectious diseases and disorders of the immune system. Our dedicated team is a focused and interactive group involved in pursuing innovative biomedical research and technologies targeted towards the development of novel therapeutics.
(For more news releases, click here)
